| Original language | English (US) |
|---|---|
| Pages (from-to) | 299-302 |
| Number of pages | 4 |
| Journal | Annals of Allergy, Asthma and Immunology |
| Volume | 126 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2021 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Eosinophilic esophagitis may persist after discontinuation of oral immunotherapy. / Hamant, Laura; Freeman, Catherine; Garg, Shipra et al.
In: Annals of Allergy, Asthma and Immunology, Vol. 126, No. 3, 03.2021, p. 299-302.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Eosinophilic esophagitis may persist after discontinuation of oral immunotherapy
AU - Hamant, Laura
AU - Freeman, Catherine
AU - Garg, Shipra
AU - Wright, Benjamin L.
AU - Schroeder, Shauna
N1 - Funding Information: Funding : Dr Wright reports receiving funding from the Arizona Biomedical Research Commission (ADHS18-198880), the Mayo Foundation, and the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR (U54 AI117804) is a part of the Rare Diseases Clinical Research Network , an initiative of the Office of Rare Diseases Research, the National Center for Advancing Translational Sciences , and is funded through a collaboration among the National Institute of Allergy and Infectious Diseases , the National Institute of Diabetes and Digestive and Kidney Diseases , and the National Center for Advancing Translational Sciences . CEGIR is also supported by patient advocacy groups including the American Partnership for Eosinophilic Disorders , Campaign Urging Research for Eosinophilic Diseases, and Eosinophilic Family Coalition. As a member of the Rare Disease Clinical Research Network, CEGIR is also supported by its Data Management and Coordinating Center (U2CTR002818). Funding Information: Disclosures: Dr Wright has received research funding from Allakos, Inc. Dr Schroeder has received research funding from Allakos, Inc; Regeneron Pharmaceuticals , Inc; and Takeda Pharmaceutical Company Ltd. The remaining authors have no conflicts of interest to report. Funding Information: Disclosures: Dr Wright has received research funding from Allakos, Inc. Dr Schroeder has received research funding from Allakos, Inc; Regeneron Pharmaceuticals, Inc; and Takeda Pharmaceutical Company Ltd. The remaining authors have no conflicts of interest to report.Funding: Dr Wright reports receiving funding from the Arizona Biomedical Research Commission (ADHS18-198880), the Mayo Foundation, and the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR (U54 AI117804) is a part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, the National Center for Advancing Translational Sciences, and is funded through a collaboration among the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Center for Advancing Translational Sciences. CEGIR is also supported by patient advocacy groups including the American Partnership for Eosinophilic Disorders, Campaign Urging Research for Eosinophilic Diseases, and Eosinophilic Family Coalition. As a member of the Rare Disease Clinical Research Network, CEGIR is also supported by its Data Management and Coordinating Center (U2CTR002818).
PY - 2021/3
Y1 - 2021/3
UR - http://www.scopus.com/inward/record.url?scp=85098948838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098948838&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2020.12.007
DO - 10.1016/j.anai.2020.12.007
M3 - Article
C2 - 33340664
AN - SCOPUS:85098948838
SN - 1081-1206
VL - 126
SP - 299
EP - 302
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 3
ER -